SCHEMBL6868166

SCHEMBL6868166

CCCCCc1[c]cccc1O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BID P55957 3/20 0.41
MCL1 Q07820 3/20 0.41
BCL2L1 Q07817 2/20 0.41
BAK1 Q16611 2/20 0.41
KAT8 Q9H7Z6 2/20 0.41
SAE1 Q9UBE0 2/20 0.41
PPARG P37231 1/20 0.41
PPARA Q07869 1/20 0.41
EP300 Q09472 1/20 0.41
KAT2A Q92830 1/20 0.41
KAT2B Q92831 1/20 0.41
KAT5 Q92993 1/20 0.41
ESR1 P03372 2/20 0.40
ADRA2A P08913 2/20 0.40
ADORA3 P0DMS8 2/20 0.40
TACR2 P21452 2/20 0.40
SLC6A2 P23975 2/20 0.40
SLC6A4 P31645 2/20 0.40
SLC6A3 Q01959 2/20 0.40
TP53 P04637 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5269764 0.98 BID (0.44) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL5270426 0.98 BID (0.44) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL5271614 0.98 BID (0.44) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL5269201 0.98 BID (0.44) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL3235877 0.98 BID (0.44) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL5272182 0.98 BID (0.44) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL6222946 0.94 TYR (0.39) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL9359701 0.86 CNR1 (0.35) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL9756310 0.83 CA2 (0.33)
SCHEMBL16719748 0.81 CA2 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023182327-A1 POSITIVE PHOTOSENSITIVE RESIN COMPOSITION, CURED PRODUCT, ORGANIC EL DISPLAY DEVICE, AND METHOD FOR PRODUCING CURED PRODUCT 東レ株式会社 2023-09-28 WO disclosed
CN-115698854-A Photosensitive resin composition, cured product, display device, semiconductor device, and method for producing cured product 东丽株式会社 2023-02-03 CN disclosed
CN-111742246-B Antireflection film and multilayer film having antireflection film 三菱瓦斯化学株式会社 2022-06-17 CN disclosed
CN-113574420-A Laminate for antireflection film, and method for producing laminate for antireflection film 三菱瓦斯化学株式会社 2021-10-29 CN disclosed
CN-113302035-A Antireflection film and multilayer film having antireflection film 三菱瓦斯化学株式会社 2021-08-24 CN disclosed
WO-2021140927-A1 RETARDATION FILM AND APPLICATIONS THEREOF 大阪ガスケミカル株式会社 2021-07-15 WO disclosed
WO-2021131942-A1 FLUORENE DERIVATIVE, METHOD FOR PRODUCING SAME, AND APPLICATION OF SAME 大阪ガスケミカル株式会社 2021-07-01 WO disclosed
WO-2020213470-A1 DICARBOXYLIC ACIDS, AND PRODUCTION METHOD AND USE THEREOF 大阪ガスケミカル株式会社 2020-10-22 WO disclosed
CN-111742246-A Antireflection film and multilayer film having antireflection film 三菱瓦斯化学株式会社 2020-10-02 CN disclosed
US-20040024209-A1 1-Aryl-4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents SCHNUTE MARK E (US) 2004-02-05 US disclosed
US-6653307-B2 Such as N-(4-chlorobenzyl)-6-(4-morpholinylmethyl)-4-oxo-1-phenyl-1,4-dihydro-3-quinolinecarboxamide for treatment of herpes virus; viral DNA polymerase inhibitors PHARMACIA & UPJOHN COMPANY 2003-11-25 US disclosed
EP-1292575-A2 1-ARYL-4-OXO-1,4-DIHYDRO-3-QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2003-03-19 EP disclosed
US-20020103220-A1 1-Aryl-4oxo-1,4-Dihydro-3-quinolinecarboxamides as antiviral agents PHARMACIA & UPJOHN COMPANY 2002-08-01 US disclosed
WO-2001098275-A2 1-ARYL-4-OXO-1,4-DIHYDRO-3-QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2001-12-27 WO disclosed
EP-0457730-B1 Process for preparation of thioderivatives of alkylhydroxyanilinotriazine CIBA GEIGY AG (CH) 1994-11-09 EP disclosed
US-5086173-A Hydrogenating in presence of palladium catalyst without isolating the intermediates CIBA-GEIGY CORPORATION (US) 1992-02-04 US disclosed
EP-0457730-A2 Process for preparation of thioderivatives of alkylhydroxyanilinotriazine CIBA-GEIGY AG (CH) 1991-11-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040024209-A1 1-Aryl-4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents ZC3HAV1, ZC3HAV1L, IRF3 BID 923/4885MCL1 448/4885BCL2L1 321/4885
US-20020103220-A1 1-Aryl-4oxo-1,4-Dihydro-3-quinolinecarboxamides as antiviral agents ZC3HAV1, IRF3, ZC3HAV1L BID 1239/4885MCL1 540/4885BCL2L1 444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.